PF-06741086

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hemophilia aSevere Hemophilia aHemophilia

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

1

Hemlibra

Roche

Phase 3

162

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

23

Eptacog Alfa

Novo Nordisk

Phase 3

14

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

15

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Phase 3

36

Recombinant Factor VIII

Bayer

Phase 3

27

Translarna

PPTC Therapeutics

Phase 2

18

Rfviia

Roche

Phase 3

19

Marstacimab

Pfizer

Phase 3

110

Refacto

Pfizer

Phase 3

4Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hemophilia3 trials

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Completed·Pfizer·Phase 1·NCT04878731·6 enrolled

PF-06741086 Multiple Dose Study in Severe Hemophilia

Completed·Pfizer·Phase 2·NCT02974855·27 enrolled

PF-06741086 Long-term Treatment in Severe Hemophilia

Completed·Pfizer·Phase 2·NCT03363321·20 enrolled

Severe Hemophilia a1 trial

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Completed·Pfizer·Phase 3·NCT03938792·189 enrolled

Hemophilia A1 trial

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS

Recruiting·Pfizer·Phase 3·NCT05145127·245 enrolled

Unspecified1 trial

Dose Escalation Study of PF-06741086 In Healthy Subjects

Completed·Pfizer·Phase 1·NCT02531815·41 enrolled

Details

Drug Info

Related News